deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT00322101

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Sponsor: Fred Hutchinson Cancer Center

Conditions Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome Acute Myeloid Leukemia/Transient Myeloproliferative Disorder Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myeloid Leukemia in Remission Childhood Acute Myeloid Leukemia in Remission Childhood Myelodysplastic Syndromes Myelodysplastic Syndrome With Isolated Del(5q) Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndromes de Novo Myelodysplastic Syndromes
Interventions allogeneic hematopoietic stem cell transplantation busulfan cyclophosphamide cyclosporine cytogenetic analysis flow cytometry fludarabine phosphate fluorescence in situ hybridization laboratory biomarker analysis methotrexate mycophenolate mofetil nonmyeloablative allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation pharmacological study polymorphism analysis tacrolimus total-body irradiation
Updated 9 times since 2017 Last updated: Oct 23, 2014 Started: Jan 31, 2006 Primary completion: Apr 30, 2012 Completion: Oct 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome and Acute Myeloid Leukemia/Transient Myeloproliferative Disorder and is currently completed. Fred Hutchinson Cancer Center leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~May 2022 · 16 months · monthly snapshotCompleted~May 2022 – ~Dec 2022 · 7 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

  5. May 2022 — Dec 2022 [monthly]

    Completed PHASE3

▶ Show 4 earlier versions

  1. Jan 2021 — May 2022 [monthly]

    Completed PHASE3

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations